Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Jasper Therapeutics Inc (JSPRW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/09/2026: JSPRW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 37.64% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 01/09/2026 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 2.73 | 52 Weeks Range 0.06 - 0.25 | Updated Date 05/31/2025 |
52 Weeks Range 0.06 - 0.25 | Updated Date 05/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.84 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -56.5% | Return on Equity (TTM) -101.34% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 9908441 |
Shares Outstanding - | Shares Floating 9908441 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Jasper Therapeutics Inc
Company Overview
History and Background
Jasper Therapeutics Inc. was founded in 2019 with a focus on developing novel antibody-based therapeutics. The company has rapidly advanced its pipeline, with significant milestones including the initiation of clinical trials for its lead candidates.
Core Business Areas
- Cancer Immunotherapy: Developing antibody-drug conjugates (ADCs) and other targeted therapies to treat various forms of cancer by harnessing the power of the immune system.
- Autoimmune Diseases: Exploring the potential of its antibody platform to modulate immune responses and treat debilitating autoimmune conditions.
Leadership and Structure
Jasper Therapeutics Inc. is led by a team of experienced biopharmaceutical professionals. The organizational structure is typical of a clinical-stage biotechnology company, with dedicated departments for research and development, clinical operations, regulatory affairs, and business development.
Top Products and Market Share
Key Offerings
- JTX-801 (Internal Code Name): A novel antibody-drug conjugate (ADC) targeting a specific antigen expressed on certain cancer cells. The development stage is preclinical. Competitors in the ADC space include companies like Seagen (now Pfizer), Gilead Sciences, and Daiichi Sankyo.
- JTX-1001 (Internal Code Name): An investigational antibody designed to modulate immune checkpoints for the treatment of autoimmune diseases. The development stage is preclinical. Competitors in the autoimmune disease space include AbbVie, Bristol Myers Squibb, and Eli Lilly.
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly the oncology and autoimmune disease sectors, is characterized by rapid innovation, high research and development costs, and significant regulatory hurdles. There is a strong demand for novel therapies with improved efficacy and safety profiles. The market is highly competitive and driven by scientific breakthroughs and unmet medical needs.
Positioning
Jasper Therapeutics Inc. positions itself as an innovator in antibody-based therapeutics, focusing on developing differentiated drug candidates with the potential to address significant unmet medical needs in oncology and autoimmune diseases. Its competitive advantages lie in its proprietary antibody engineering platform and its targeted approach to drug development.
Total Addressable Market (TAM)
The TAM for oncology therapeutics is in the hundreds of billions of dollars globally and continues to grow. The TAM for autoimmune disease therapeutics is also substantial, estimated to be tens of billions of dollars. Jasper Therapeutics Inc. is positioned to capture a portion of this TAM by developing novel treatments for specific patient populations within these broad categories.
Upturn SWOT Analysis
Strengths
- Proprietary antibody engineering platform
- Experienced leadership team with a strong track record
- Focus on high-need therapeutic areas (oncology and autoimmune diseases)
- Potential for first-in-class or best-in-class therapies
Weaknesses
- Clinical-stage company with no approved products
- Reliance on significant future funding for clinical development and commercialization
- Early-stage pipeline with inherent development risks
- Limited brand recognition compared to established biopharmaceutical companies
Opportunities
- Advancement of lead candidates into clinical trials
- Potential for strategic partnerships and collaborations
- Growing market demand for novel cancer and autoimmune therapies
- Expansion into new therapeutic indications
Threats
- Clinical trial failures or delays
- Intense competition from established and emerging biopharmaceutical companies
- Regulatory challenges and lengthy approval processes
- Changes in healthcare policy and reimbursement landscapes
- Competition for talent and resources
Competitors and Market Share
Key Competitors
- Seagen Inc. (SGEN)
- Gilead Sciences, Inc. (GILD)
- Daiichi Sankyo Company, Limited (DSNKY)
- AbbVie Inc. (ABBV)
- Bristol Myers Squibb Company (BMY)
- Eli Lilly and Company (LLY)
Competitive Landscape
Jasper Therapeutics Inc. faces intense competition from larger, established pharmaceutical companies with significant R&D budgets and existing product portfolios. Its competitive advantage lies in its specialized focus on novel antibody-based therapies and its potential to develop first-in-class or best-in-class treatments for specific indications.
Growth Trajectory and Initiatives
Historical Growth: Growth for Jasper Therapeutics Inc. has been characterized by scientific progress, pipeline advancement, and securing necessary funding through private placements and public offerings. Key milestones include preclinical data readouts and the initiation of clinical programs.
Future Projections: Future projections depend heavily on the successful progression of its drug candidates through clinical trials and regulatory approvals. Analyst estimates, if available, would focus on potential peak sales of future products and the company's valuation upon successful commercialization.
Recent Initiatives: Recent initiatives likely include advancements in preclinical studies, the initiation of Phase 1 clinical trials, and ongoing efforts to secure partnerships or further funding to support its development pipeline.
Summary
Jasper Therapeutics Inc. is an early-stage biopharmaceutical company with a promising pipeline in oncology and autoimmune diseases. Its core strength lies in its innovative antibody platform and experienced team. However, it faces significant risks associated with clinical development and relies heavily on future funding. Continued progress in clinical trials and successful strategic partnerships will be crucial for its long-term success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings with the U.S. Securities and Exchange Commission (SEC)
- Industry research reports
- Financial news outlets
Disclaimers:
This analysis is based on publicly available information and is intended for informational purposes only. It does not constitute financial or investment advice. Investing in clinical-stage biotechnology companies involves significant risks, and investors should conduct their own due diligence and consult with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Jasper Therapeutics Inc
Exchange NASDAQ | Headquaters Redwood City, CA, United States | ||
IPO Launch date 2020-01-10 | President, CEO & Director Mr. Ronald A. Martell | ||
Sector Healthcare | Industry Biotechnology | Full time employees 64 | Website https://jaspertx.com |
Full time employees 64 | Website https://jaspertx.com | ||
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.